home / stock / xynpw / xynpw quote
Last: | $ |
---|---|
Change Percent: | -15.83% |
Open: | $0.0101 |
Close: | $0.0101 |
High: | $0.0101 |
Low: | $0.0101 |
Volume: | 13,928 |
Last Trade Date Time: | 02/12/2020 04:42:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $0.0101 | $0.0101 | $0.0101 | $0.0101 | 13,928 | 02-12-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-30-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-29-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-28-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-27-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-24-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-23-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-22-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-21-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-20-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-17-2020 |
$ | $N/A | $0.012 | $N/A | $N/A | 0 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Xynomic Pharmaceuticals Holdings Inc Warrants (15/05/2024) Company Name:
XYNPW Stock Symbol:
NASDAQ Market:
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-T...
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase ...
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead cand...